Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2017 1
2018 2
2019 4
2020 6
2021 9
2022 6
2023 1
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

27 results

Results by year

Filters applied: . Clear all
Page 1
Immunogenic oncolysis by tigilanol tiglate.
Pol JG, Lizarralde-Guerrero M, Kroemer G. Pol JG, et al. Oncoimmunology. 2024 May 27;13(1):2360230. doi: 10.1080/2162402X.2024.2360230. eCollection 2024. Oncoimmunology. 2024. PMID: 38812571 Free PMC article.
Tigilanol tiglate is an oncolytic small molecule that is undergoing clinical trials. A recent study revealed the capacity of this pyroptosis inducer to elicit hallmarks of immunogenic cell death. In addition, intratumoral injection of tigilanol tiglate …
Tigilanol tiglate is an oncolytic small molecule that is undergoing clinical trials. A recent study revealed the capacity of t …
Tigilanol Tiglate-Mediated Margins: A Comparison With Surgical Margins in Successful Treatment of Canine Mast Cell Tumours.
De Ridder T, Reddell P, Jones P, Brown G, Campbell J. De Ridder T, et al. Front Vet Sci. 2021 Dec 15;8:764800. doi: 10.3389/fvets.2021.764800. eCollection 2021. Front Vet Sci. 2021. PMID: 34977208 Free PMC article.
Tigilanol tiglate (TT) is a novel small molecule registered as a veterinary pharmaceutical for intratumoural treatment of canine mast cell tumours (MCTs). ...
Tigilanol tiglate (TT) is a novel small molecule registered as a veterinary pharmaceutical for intratumoural treatment of cani …
Identification of Gene Biomarkers for Tigilanol Tiglate Content in Fontainea picrosperma.
Mitu SA, Stewart P, Tran TD, Reddell PW, Cummins SF, Ogbourne SM. Mitu SA, et al. Molecules. 2022 Jun 21;27(13):3980. doi: 10.3390/molecules27133980. Molecules. 2022. PMID: 35807225 Free PMC article.
Tigilanol tiglate (EBC-46) is a small-molecule natural product under development for the treatment of cancers in humans and companion animals. ...
Tigilanol tiglate (EBC-46) is a small-molecule natural product under development for the treatment of cancers in humans and co …
Practical synthesis of the therapeutic leads tigilanol tiglate and its analogues.
Wender PA, Gentry ZO, Fanelli DJ, Luu-Nguyen QH, McAteer OD, Njoo E. Wender PA, et al. Nat Chem. 2022 Dec;14(12):1421-1426. doi: 10.1038/s41557-022-01048-2. Epub 2022 Oct 3. Nat Chem. 2022. PMID: 36192432 Free PMC article.
Tigilanol tiglate is a natural product diterpenoid in clinical trials for the treatment of a broad range of cancers. ...Here we report a practical laboratory synthesis of tigilanol tiglate that proceeds in 12 steps (12% overall yield, >80% average y …
Tigilanol tiglate is a natural product diterpenoid in clinical trials for the treatment of a broad range of cancers. ...Here w …
Use of the Intratumoural Anticancer Drug Tigilanol Tiglate in Two Horses.
De Ridder T, Ruppin M, Wheeless M, Williams S, Reddell P. De Ridder T, et al. Front Vet Sci. 2020 Sep 9;7:639. doi: 10.3389/fvets.2020.00639. eCollection 2020. Front Vet Sci. 2020. PMID: 33033726 Free PMC article.
Tigilanol tiglate is a novel small molecule approved as a veterinary pharmaceutical in Europe for intratumoural treatment of non-metastatic, non-resectable canine mast cell tumors. ...The results from this study support continued development and evaluation of tig …
Tigilanol tiglate is a novel small molecule approved as a veterinary pharmaceutical in Europe for intratumoural treatment of n …
Treatment of multiple synchronous canine mast cell tumours using intratumoural tigilanol tiglate.
Brown GK, Finlay JR, Straw RC, Ziea JY, Leung B, O'Connell K, Thomson MJ, Campbell JE, Jones PD, Reddell P. Brown GK, et al. Front Vet Sci. 2022 Oct 26;9:1003165. doi: 10.3389/fvets.2022.1003165. eCollection 2022. Front Vet Sci. 2022. PMID: 36387404 Free PMC article.
A complete response was recorded in 26 (81%) of the individual MCTs on Day 28 after a single tigilanol tiglate injection. Of the 6 initially non-responsive MCTs, one achieved a complete response after a further tigilanol tiglate treatment. ...Overall, …
A complete response was recorded in 26 (81%) of the individual MCTs on Day 28 after a single tigilanol tiglate injection. Of t …
Activation of PKC supports the anticancer activity of tigilanol tiglate and related epoxytiglianes.
Cullen JK, Boyle GM, Yap PY, Elmlinger S, Simmons JL, Broit N, Johns J, Ferguson B, Maslovskaya LA, Savchenko AI, Mirzayans PM, Porzelle A, Bernhardt PV, Gordon VA, Reddell PW, Pagani A, Appendino G, Parsons PG, Williams CM. Cullen JK, et al. Sci Rep. 2021 Jan 8;11(1):207. doi: 10.1038/s41598-020-80397-9. Sci Rep. 2021. PMID: 33420238 Free PMC article.
To explore the hypothesis that activation, rather than inhibition, of these isoforms is critical for anticancer activity, we isolated and characterized a family of 16 novel phorboids closely-related to tigilanol tiglate (EBC-46), a PKC-activating epoxytigliane showi …
To explore the hypothesis that activation, rather than inhibition, of these isoforms is critical for anticancer activity, we isolated and ch …
Tigilanol tiglate is an oncolytic small molecule that induces immunogenic cell death and enhances the response of both target and non-injected tumors to immune checkpoint blockade.
Cullen JK, Yap PY, Ferguson B, Bruce ZC, Koyama M, Handoko H, Hendrawan K, Simmons JL, Brooks KM, Johns J, Wilson ES, de Souza MMA, Broit N, Stewart P, Shelley D, McMahon T, Ogbourne SM, Nguyen TH, Lim YC, Pagani A, Appendino G, Gordon VA, Reddell PW, Boyle GM, Parsons PG. Cullen JK, et al. J Immunother Cancer. 2024 Apr 24;12(4):e006602. doi: 10.1136/jitc-2022-006602. J Immunother Cancer. 2024. PMID: 38658031 Free PMC article.
BACKGROUND: Tigilanol tiglate (TT) is a protein kinase C (PKC)/C1 domain activator currently being developed as an intralesional agent for the treatment of various (sub)cutaneous malignancies. ...
BACKGROUND: Tigilanol tiglate (TT) is a protein kinase C (PKC)/C1 domain activator currently being developed as an intralesion …
Intratumoural Treatment of 18 Cytologically Diagnosed Canine High-Grade Mast Cell Tumours With Tigilanol Tiglate.
Brown GK, Campbell JE, Jones PD, De Ridder TR, Reddell P, Johannes CM. Brown GK, et al. Front Vet Sci. 2021 Aug 27;8:675804. doi: 10.3389/fvets.2021.675804. eCollection 2021. Front Vet Sci. 2021. PMID: 34513966 Free PMC article.
The primary aim of this retrospective study was to assess the efficacy of intratumoural tigilanol tiglate (TT) as a local treatment option. Eighteen dogs with mast cell tumours (MCT) cytologically diagnosed by veterinary pathologists as either high-grade or suspecte …
The primary aim of this retrospective study was to assess the efficacy of intratumoural tigilanol tiglate (TT) as a local trea …
[Successful local treatment of a digital canine mast cell tumour with Tigilanol Tiglate].
Gasser K. Gasser K. Tierarztl Prax Ausg K Kleintiere Heimtiere. 2022 Jun;50(3):225-231. doi: 10.1055/a-1844-8554. Epub 2022 Jul 5. Tierarztl Prax Ausg K Kleintiere Heimtiere. 2022. PMID: 35790169 German.
Surgical excision is currently the recommended treatment for resectable, nonmetastatic mast cell tumours. Recently, Tigilanol tiglate has become available as a novel intratumoral treatment modality for a subset of cutaneous and subcutaneous mast cell tumours. ...
Surgical excision is currently the recommended treatment for resectable, nonmetastatic mast cell tumours. Recently, Tigilanol tigl …
27 results